Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in non-diabetic patients after acute anterior STEMI treated with primary PCI
IRCT20221227056950N1Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of empagliflozin in myocardial infarction (MI), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Change in left ventricular ejection fraction. Started Jan 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20221227056950N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221227056950N1.